Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Teva Pharmaceutical
Fierce Biotech
Teva saddles up as bidder for bankrupt BioXcel’s CNS assets
BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.
Nick Paul Taylor
Aug 28, 2026 9:17am
Teva's patent and communications strategies in Turkey face probe
Aug 26, 2026 8:15am
Aurinia deal with Teva keeps Lupkynis generic in check until '36
Aug 20, 2026 11:28am
J&J’s Tremfya remains on top in Q2 pharma ad spending league
Jul 21, 2026 9:10am
How biosimilar developers are embracing next phase of US market
Jul 6, 2026 10:03am
Teva to lay off 250 at for-sale API unit: report
Jun 10, 2026 10:56am
